Each NeuroPI module is prepared by distinguished faculty who are acknowledged leaders in their respective fields. Each module is composed of a set of multiple-choice items with preferred responses, instructions on how to collect cases to assess one’s practice, and educational resources related to the measure(s) that can be used for design and implementation of an improvement plan. Participants are able to evaluate their performance comparing current practice with measures and best practices to their post-intervention results to assess whether improvement goals have been achieved and that changes have occurred in their practice.
Members: FREE $199.00*
*Free access is limited to one course at a time for eligible members.
Through this program, the learner will be able to:
- Define the need to obtain history and physical examination for opioid users.
- Evaluate the need and risk for opioid misuse using a validated instrument.
- Describe the need to document a patient signed opioid treatment agreement.
- Assess the need for consideration of non-pharmacologic interventions.
- Recognize the need for follow-up evaluations for COT patients.
- Justify the need for documented state prescription drug monitoring program checks during COT.
- History and Physical Examination for Opioid Users.
- Evaluation and Interview for Risk of Opioid Misuse.
- Documentation of Signed Opioid Treatment Agreement.
- Consideration of Non-Pharmacologic Interventions.
- Chronic Opioid Therapy Follow-up Evaluation.
- Use of State Prescription Drug Monitoring Programs.
- Interpersonal Skills and Communication
- Medical Knowledge
- Patient Care
- Practice-based Learning and Improvement
For Patients Prescribed Opiates For Non-cancer Pain:
As a result of this program, the participant will determine individual practice gaps and address them through a performance improvement plan designed to improve competence, performance, and patient outcomes.
Date of Release
June 23, 2016
This module is eligible for CME credits for three years from the release date.
NeuroPI Data Terms & Conditions
The American Academy of Neurology Institute (AANI) no longer requires You (NeuroPI and aan.com user) to provide full date of service (day/month/year); only year of service will be transmitted to and stored by AANI. All previously collected "day" and "month" from date of service records have been deleted from the AANI's NeuroPI database. Accordingly, for NeuroPI, AANI is not requesting or storing any "protected health information" or "limited data sets" as defined by the regulations issued under the Health Insurance Portability and Accountability Act of 1996. The patient data You submit to the AANI through NeuroPI is de-identified health information. You must track patients separately from NeuroPI. Within the NeuroPI modules, Your patients will be identified using a 4-digit patient code that You create. Any other identifying information is strictly prohibited. Please use the NeuroPI Patient Tracker to create Your 4-digit patient codes for Your personal reference. The NeuroPI Patient Tracker must not be shared with AANI.
The American Academy of Neurology Institute either owns or has permission to use all of the NeuroPI module content. You may use these modules for your personal, noncommercial use, but please send permissions requests for any other uses to NeuroPI@aan.com. All of the individual de-identified health information you submit to the AANI through NeuroPI is confidential. Your maintenance of certification ("MOC") credit information is transmitted to the American Board of Psychiatry and Neurology (ABPN) once You've completed a module. You can opt-out of this service in NeuroTracker. Please note, AANI is not a certifying board and members are encouraged to contact ABPN for the most up-to-date information on MOC requirements. You acknowledge that AANI is and shall be deemed the owner of all rights to the aggregate, de-identified data submitted to NeuroPI and subsets of the aggregate data, any and all reports based on the aggregate, de-identified data, and all trademarks and trade secrets arising from or reflected in NeuroPI (collectively, "Aggregate Data"), with the exception of your individual data. AANI has full and unencumbered rights to publish, disclose, distribute, market, sell, and create derivatives of, Aggregate Data in any form.
GARY M. FRANKLIN, MD, MPH, FAAN
Research Professor, University of Washington, Seattle, WA
Medical Director, Washington State Dept of Labor and Industries, Tumwater, WA
*Dr. Franklin has nothing to disclose.
CHARLES ARGOFF, MD
Professor of Neurology
Director, Comprehensive Pain Center Albany Medical College/Albany Medical Center, Albany, NY
*Dr. Argoff has received personal compensation for activities with Allergan, Depomed, Xenoport, Astra Zenica, Iroko, Teva, Purdue, Pfizer, Nektar, Janssen, Collegium, Daiichi Sakyo, Scilex, Endo, Zogenix, and Accorda Pain Medicine as a speaker and/or advisory board member. Dr. Argoff has received personal comensation in an editorial capacity for Pain Medicine. Dr. Argoff has received research support from Albany Medical College, Endo, Lilly, Forest Labs, Gruenthal, Alder, and Dong Therapeutics
DONALD J. IVERSON, MD, FAAN
Humboldt Neurological Medical Group
*Dr. Iverson has nothing to disclose.
Program Manager, Online Learning
*Ms. Chamberlain has nothing to disclose.
+ Unlabeled Use of Products/Investigational Use Disclosure